Evidence map›Paper›PMID 38826403›Full record

ArticlebioRxiv : the preprint server for biology2024

Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers.

Maxim Kuznetsov, Vikram Adhikarla, Enrico Caserta, Xiuli Wang, John E Shively, Flavia Pichiorri, Russell C Rockne

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Maxim KuznetsovDepartment of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.ORCID 0000-0002-0004-9002
Vikram AdhikarlaDepartment of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.
Enrico CasertaDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.
Xiuli WangDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, United States.
John E ShivelyDepartment of Molecular Imaging & Therapy, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, United States.
Flavia PichiorriDepartment of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.
Russell C RockneDepartment of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA, United States.ORCID 0000-0002-1557-159X

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI John Charles Williams · 1985 to 2026
$86.3M
Exploring the preclinical relevance of therapeutic radiolabeled daratumumab (anti-CD38) in combination with anti-CS1 CAR T cells as a novel combinatorial treatment for multiple myelomaR01CA238429 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI PICHIORRI, FLAVIA, ROCKNE, RUSSELL CHRISTIAN · 2019 to 2023
$2.0M
Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic InterventionsR50CA252135 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CASERTA, ENRICO · 2021 to 2025
$564k
NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA238429NCI NIH HHS R50 CA252135
6 · The paper itself

Abstract

Targeted radionuclide therapy is based on injections of cancer-specific molecules conjugated with radioactive nuclides. Despite the specificity of this treatment, it is not devoid of side-effects limiting its use and is especially harmful for rapidly proliferating organs well perfused by blood, like bone marrow. Optimization of radioconjugates administration accounting for toxicity constraints can increase treatment efficacy. Based on our experiments on disseminated multiple myeloma mouse model treated by

Identifiers

PMID38826403
PMCPMC11142146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.